Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Thrombosis 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Disease 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytopenia 1Thoracic Neoplasms 1Skin Neoplasms 1Pituitary Neoplasms 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Papillomavirus Infections 1

Interventions

Thyrotropin Alfa 2cabozantinib 1Thyrotropin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Thyroid Cancer, Papillary × Injections × Clear all
NCT00295763 2015-03-18

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Sanofi

Phase 3 Completed
61 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡